Clearside Biomedical Stock Debt To Equity
| CLM Stock | EUR 0.93 0.06 6.06% |
Clearside Biomedical fundamentals help investors to digest information that contributes to Clearside Biomedical's financial success or failures. It also enables traders to predict the movement of Clearside Stock. The fundamental analysis module provides a way to measure Clearside Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Clearside Biomedical stock.
Clearside |
Clearside Biomedical Company Debt To Equity Analysis
Clearside Biomedical's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Clearside Biomedical has a Debt To Equity of 0.0%. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Debt To Equity (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
Did you try this?
Run Investing Opportunities Now
Investing OpportunitiesBuild portfolios using our predefined set of ideas and optimize them against your investing preferences |
| All Next | Launch Module |
Clearside Fundamentals
| Current Valuation | 17.17 M | |||
| Price To Book | 3.77 X | |||
| Price To Sales | 2.67 X | |||
| Revenue | 29.57 M | |||
| EBITDA | (449 K) | |||
| Net Income | 376 K | |||
| Cash Flow From Operations | (10.73 M) | |||
| Market Capitalization | 4.14 M | |||
| Total Asset | 42.9 M | |||
| Net Asset | 42.9 M |
About Clearside Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Clearside Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clearside Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clearside Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Clearside Stock Analysis
When running Clearside Biomedical's price analysis, check to measure Clearside Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearside Biomedical is operating at the current time. Most of Clearside Biomedical's value examination focuses on studying past and present price action to predict the probability of Clearside Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearside Biomedical's price. Additionally, you may evaluate how the addition of Clearside Biomedical to your portfolios can decrease your overall portfolio volatility.